NCT04553978

A Single Oral Dose, Crossover Comparative PK Study of WD-1603 in Healthy Subjects Under Fasting Conditions

An Open Label, Balanced, Randomised, 2-treatment, 2-period, 2-sequence, Single Oral Dose, Corssover Comparative PK Study of WD-1603 in Normal, Healthy, Adult Human Subjects Under Fasting Conditions

• Status: Unknown
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 8 (estimated)
• Sponsor: Hong Kong WD Pharmaceutical Co., Limited · Industry
• Sex: All
• Age: 18 Years – 45 Years
• Healthy volunteers: Accepted

Summary

An open label, balanced, randomized, two-treatment, two-period, two-sequence, single oral dose, crossover comparative Pharmacokinetics study of WD-1603 extended-release carbidopa/levodopa tablets in normal, healthy, adult human subjects under fasting conditions

Detailed description

This is an open label, balanced, randomized, two-treatment, two-period, two-sequence, single oral dose, crossover comparative Pharmacokinetics study of WD-1603 extended-release carbidopa/levodopa tablets in normal, healthy, adult human subjects under fasting conditions.

Conditions

• Parkinson Disease

Interventions

Type	Name	Description
DRUG	WD-1603	WD-1603 CARBIDOPA/LEVODOPA EXTENDED-RELEASE TABLETS

Timeline

• Start date: 2020-09-18
• Primary completion: 2021-03-18
• Completion: 2021-03-18
• First posted: 2020-09-18
• Last updated: 2020-09-22

Regulatory

• FDA-regulated drug study